Results 191 to 200 of about 519,424 (350)

Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]

Cureus
Al-Shaker AN, Agarwal A, Saeed MT, Marney Z.   +3 more
europepmc   +1 more source

Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

, 2012
Lisa A. Tobin, Caroline Robert, Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson, Feyruz V. Rassool   +6 more
openalex   +2 more sources

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors [PDF]

, 2015
Monika A. Davare, Nadeem A. Vellore, Jacob P. Wagner, Christopher A. Eide, James R. Goodman, Alexander Drilon, Michael W. Deininger, Thomas O’Hare, Brian Druker   +8 more
openalex   +1 more source

Tyrosine Kinase Inhibitor [PDF]

, 2020
openaire   +1 more source

Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring

Advanced Science, EarlyView.
Scars exhibit vascular abnormal alterations, including upregulated NRP1 expression in endothelial cells, increased vascular density and branching, compromised vessel wall integrity, and incomplete pericyte coverage. Therapeutic targeting of NRP1 through hydrogel spray delivery offers a promising approach to normalize aberrant vasculature and prevent ...
Yu Wang, Xin Zhou, Min Liu, Meimei Huang, Peirong Chen, Xinying Li, Fangchao Xue, Wenyan Zhao, Di Liu, Lang Li, Yuangang Lu, Wen Zeng   +11 more
wiley   +1 more source

Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]

Front Cell Dev Biol
Tiedemann L, Gorantla SP, Ahlf P, Schmidt LS, Pott C, Litterst M, Waetzig V, Nagel I, Ruemenapp J, von Bubnoff N, Cascorbi I, Kaehler M.   +11 more
europepmc   +1 more source

Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside

, 2017
Anat Ben-Shlomo, Odelia Cooper
openalex   +2 more sources

Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors [PDF]

, 2013
Masashi Niwakawa, Raizo Yamaguchi, Yusuke Onozawa, Hirofumi Yasui, Keisei Taku, Tateaki Naito, Shiro Akinaga, Narikazu Boku, Nobuyuki Yamamoto   +8 more
openalex   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

Advanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang, Qian Shen, Yao Lin, Jing Zhu, Xiaolan Zhu, Rui Huang, Yijia Wu, Feiyang Shen, Qian Li, Guopei Zheng, Zhe Zhang, Qian Chu, Junhao Hu, Jianfeng Shen   +13 more
wiley   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source